Risk Factors Update Summary
- The Company paused U.S. sales of ProFound AI Risk until FDA clearance, impacting revenue.
- The Company shifted to a subscription software model, with uncertain market acceptance.
- The Company incurred a net loss of approximately $4.9 million in 2023.
- The Company's OEM partners accounted for 32% of total revenue in 2023, up from 26% in 2022.
- The Company sold 1,057,814 shares of common stock in 2023, raising $2.0 million.
- The Company may experience substantial dilution if it raises additional capital through equity securities.
- The Company faces evolving U.S. and foreign laws regarding privacy, data protection, and AI.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=749660&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.